Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

November 10, 2017: By Jon Swedien


Tear Film Completes $9 Series A Round

Tear Film Innovations announced Nov. 7 it completed a $9 million Series A preferred stock funding round.

The San Diego company’s flagship product, the iLux system, is an investigational device for dry eye and is under US FDA review.

The device enables eye care professionals to provide in-office treatment of blocked meibomian glands through targeted heating and compression of affected eyelids. TFI recently completed a multi-site clinical study to demonstrate the safety and efficacy of the system.

Visionary Ventures Fund and Tigris Ventures led the financing round.

exicure-logoExicure Raises $31.4 Million in Private Financing

Exicure has raised about $31.4 million in private financing, the company announced Nov. 6.

The Skokie, Illinois, company is focused on creating drug treatments using three-dimensional spherical nucleic acid constructs. Exicure is pursuing an ophthalmic target candidate but has not disclosed the indication it is seeking. The ophthalmic target candidate would be delivered to the retina via an eye drop.

Exicure is also pursuing chronic conditions and orphan diseases in dermatology, respiratory and gastric disorders, and solid tumors.

In the initial private placement announced in September, Exicure raised approximately $20.1 million. Exicure raised more than $11.2 million in a subsequent financing, for a total of about $31.4 million.

download (2)Genisphere Completes $7 Million Capital Raise

Genisphere has completed a $7 million capital raise, the Hatfield, Pennsylvania, company announced Nov. 1

Genisphere is advancing its 3DNA nanotechnology platform for targeted drug delivery, and its product pipeline includes GL-249, a proposed preventive treatment for posterior capsule opacification (PCO).

PCO is a vision impairing disease that occurs in some adults and in most children following cataract surgery. PCO arises when myofibroblast cells grow in the capsule surrounding the surgical site and form cloudy scar tissue inside the eye that blocks vision. While PCO is treated readily by laser therapy, the procedure is neither risk free nor available in the developing world, Genisphere said.

Genisphere said the money it raised will be used to advance its 3DNA nanotechnology and to serve other corporate purposes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022